• Matinas BioPharma will consolidate its common stock in a 1-for-15 reverse split effective 12:01 a.m. ET on Sept. 28, 2026.
• Shares are expected to trade on a split-adjusted basis on the NYSE American at the open on Sept. 28 under MTNB.
• Fractional shares will not be issued; holders will receive cash in lieu of any fractional entitlement.
• Post-split ownership percentages and voting power are expected to remain largely unchanged, aside from rounding effects.
• The new CUSIP following the reverse split will be 576810 402.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042954), on September 16, 2026, and is solely responsible for the information contained therein.